Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Ibio Inc (IBIO) is now available.
iBio, Inc. has successfully sold its PD-1 agonist assets to Otsuka Pharmaceutical for an initial $1 million, with additional payments of up to $52.5 million tied to future development and commercial milestones. Originally acquired from RubrYc Therapeutics, these assets are part of a strategic move, with iBio focusing on its patented AI drug discovery platform and other immuno-oncology candidates. Details of the transaction, which do not affect other developmental milestones from the RubrYc agreement, were made public in a press release on February 26, 2024.
For a thorough assessment of IBIO stock, go to TipRanks’ Stock Analysis page.